Andrew is an academic physician with an international reputation established over more than three decades in diabetes, endocrinology, lipids and cardiovascular disease prevention.
Complementing his many years as an NHS-trained consultant physician is Andrew’s hands-on experience of developing new treatments for diabetes. This was gained as a senior research fellow at a state-of-the-art clinical research institute in California and subsequently as professor of endocrinology & metabolism and director of the Translational Medicine Institute at the Clore Life Sciences Laboratory, University of Buckingham, UK.
Andrew is accredited as a clinical specialist by the European Society of Hypertension. He is an elected council member of the Section for Lipids, Metabolism & Vascular Risk at the Royal Society of Medicine, UK as well as being a member of the Medical, Scientific & Research Committee of the cholesterol charity, Heart UK.
While Prof Krentz’s primary clinical focus is type 2 diabetes he offers expertise in obesity, diabetes prevention, lipid metabolism, hypertension, and non-alcoholic fatty liver disease. Not only are these modifiable risk factors relevant to the development of cardiovascular disease but they increase the risks of dementia and frailty thereby impairing healthy longevity.
NHS and academic posts
Currently Andrew is visiting professor of medical science in the Institute for Cardiovascular & Metabolic Research at the University of Reading, UK where he is involved in the development of a new medical school. Before his move into the life sciences and academia he was a senior consultant physician specialising in diabetes & endocrinology at University Hospital Southampton, UK.
Andrew has long recognized the importance of patient engagement in achieving long-term health goals and the pursuit of healthy ageing.